Pipeline

Disease area

Product

Compound

Indication

Phase I

Phase II

Phase III

Agitation in dementia of the Alzheimer’s type

Rexulti

Brexpiprazole

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of agitation in dementia of the Alzheimer’s type.

Find the specific study here: www.clinicaltrials.gov/NCT01922258

and www.clinicaltrials.gov/NCT03594123

 

 

      

Bipolar Mania (under review)

Rexulti

Brexpiprazole

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of bipolar mania.

For more information and study locations, please visit www.clinicaltrials.gov

 

 

      

Post-Traumatic Stress Disorder

Rexulti

Brexpiprazole

Brexpiprazole is a molecule approved as an adjunctive therapy to antidepressants in adults with major depressive disorder (US) and as a treatment in adults with schizophrenia (US, EU, CA). Brexpiprazole is further in development for the potential treatment of Post-Traumatic Stress Disorder.

For more information and study locations, please visit www.clinicaltrials.gov

 

      

 

Parkinson's Disease

 

Foliglurax

Foliglurax is a small-molecule positive allosteric modulator of group III metabotropic glutamate receptor 4 (mGluR4 PAM) for the potential oral treatment of Parkinson's disease.

Read the specific study here: www.clinicaltrials.gov/NCT03162874

 

      

 

Schizophrenia  

Lu AF11167

Lu AF11167 is a potent and selective inhibitor of the PDE10A enzyme and is in development as a monotherapy treatment of negative symptoms in clinically stable (positive symptom controlled) patients with schizophrenia.

Read the specific study here www.clinicaltrials.gov/NCT03793712

 

      

 
Under review   Lu AF35700

Lu AF35700 is currently under review in different indications.

For more information and study locations, please visit www.clinicaltrials.gov

 

      

 

Schizophrenia 2 months

Abilify Maintena

Aripiprazole once-monthly

Aripiprazole once-monthly is an intramuscular injection indicated for the treatment of schizophrenia once-monthly. It is further in development as a potential 2 months’ treatment of schizophrenia.

For more information and study locations, please visit www.clinicaltrials.gov

      

 

 

Schizophrenia/ Alzheimer’s Disease

 

Lu AF76432

Lu AF76432 is a potent and selective PDE1 inhibitor (PDE1i) and is in early development for the treatment of cognitive dysfunction, e.g. patients with schizophrenia and/or with Alzheimer’s disease.

Read the specific study here: www.clinicaltrials.gov/NCT03531229

      

 

 

Alzheimer’s Disease

  Lu AF20513

Lu AF20513 is an active immunotherapy to induce specific antibodies against pathological forms of amyloid beta (Aβ) using the patients’ own immune system in the potential treatment of Alzheimer’s disease.

Read the specific study here: www.clinicaltrials.gov/NCT03819699

      

 

 

Parkinson’s Disease

  Lu AF28996

Lu AF28996 is a D1/D2 agonist in development targeting moderate to advanced Parkinson’s disease patients with motor fluctuations.

Read the specific study here: www.clinicaltrials.gov/NCT03565094

      

   

Parkinson’s Disease

  Lu AF82422

Lu AF82422 is a human IgG1 mAb that recognizes all major species of alpha-synuclein. Extracellular alpha-synuclein is believed to play a major role in disease pathology and progression in Parkinson’s disease.

Read the specific study here www.clinicaltrials.gov/NCT03611569

      

 

 

 

 

 

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.